10X Genomics Inc vs Waste Management, Inc. — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Waste Management, Inc. trades at $233.18 (market cap $96.00B). The key difference: Waste Management, Inc. is far larger — about 17.5× 10X Genomics Inc's market cap, and Waste Management, Inc. pays a 1.48% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WM | |
|---|---|---|
Market Cap | $5.48B | $96.00B |
Sector | Health | Industrials |
52-Week High | $45.80 | $246.51 |
52-Week Low | $11.34 | $196.77 |
Enterprise Value | $5.02B | $118.73B |
Dividend Yield | — | 1.48% |
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
WM (Waste Management) trades at $233.18, down 2.56% on the day, but remains near its 52-week high of $248.13. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal steady revenue growth to $25.20 billion in 2025 and a robust 10.99% net income margin. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 results missed. Analyst sentiment is positive with a consensus buy rating and $263.57 price target, supported by a reliable dividend and strong cash flow from operations of $6.04 billion.
Outlook: WM's dominant market position, pricing power, and renewable energy initiatives support long-term growth, but high debt levels and competitive pressures pose risks. The stock offers value for income and growth investors, with potential upside to analyst targets if execution remains solid amid economic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →